1. Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
- Author
-
Kathrin Nachtkamp, Ulrich Germing, Rainer Haas, Guido Kobbe, Annika Kasprzak, Jennifer Kaivers, and Norbert Gattermann
- Subjects
Adult ,medicine.medical_specialty ,Consensus ,Health, Toxicology and Mutagenesis ,media_common.quotation_subject ,Review ,Diagnostic tools ,03 medical and health sciences ,Therapeutic approach ,0302 clinical medicine ,Health care ,medicine ,Humans ,Quality (business) ,guidelines ,Intensive care medicine ,media_common ,business.industry ,Myelodysplastic syndromes ,Public Health, Environmental and Occupational Health ,medicine.disease ,myelodysplastic syndromes ,patient reported outcome ,Clinical trial ,Action (philosophy) ,030220 oncology & carcinogenesis ,Medicine ,Patient-reported outcome ,prognosis ,business ,030215 immunology - Abstract
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.
- Published
- 2021
- Full Text
- View/download PDF